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1. Introduction 
The current definition of biomarkers includes “a characteristic that is objectively measured 
and evaluated as an indicator of normal biological processes, pathogenic processes, or 
pharmacologic responses to a therapeutic intervention (Biomarkers Definitions Working 
Group, 2001)”. Accordingly, biomarkers are usually used for detection and establishing the 
magnitude of a physiological derangement as well as to monitor a treatment.  
The role for imaging techniques and biomarkers in the diagnosis and treatment of 
myocardial infarction (MI) after percutaneous coronary intervention is well-established. 
Many candidate biomarkers emerging from genomics and proteomics research have the 
potential to serve as predictive indexes for guiding the development of interventional 
cardiology (Gerhardt  et al. 1991; Katus et al., 1991; Lindpaintner, 1997; Kong et al., 1997). 
Among them the undisputed role still play cardiac proteins like troponins or creatine 
kinase-myocardial band (CK-MB) (Alcock et al., 2010; Lim et al., 2011). Less established, 
however, is the employment of biomarkers to determine long-term, progressive, or dynamic 
risk over time in patients with advanced coronary artery disease (CAD). Biomarkers offer a 
means to track differential exposure as well as impact of exposure. As such, they reflect 
individual vulnerability, ongoing person-environment interaction, and unmeasured 
environmental factors that mediate the effect of exposures (Fig. 1). Essential to a vision of 
synergistic diagnostics is a focus on the mechanisms of diseases. Understanding what is 
happening on a molecular and cellular level, how disease actually begins, how cells begin to 
express certain proteins, influence other cells and trigger processes (atherosclerosis, 
thrombosis, calcification) will allow to develop in vitro diagnostics and imaging techniques 
to distinguish these processes. By characterizing a comprehensive set of measurable 
processes that capture diverse pathogenic aspects of CAD, a real-time systems view of 
disease activity can be generated to improve decision making. 
This chapter summarize a current view on the development of new biomarkers as a 
prognostic platform among patients at risk of CAD and upcoming complications. 
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Fig. 1. Model showing relationship of a biomarker with internal and external factors which 
have an impact on measurable and unmeasurable features of biomarker. 
2. Bone remodelling biomarkers 
About 10 years ago, the hypothesis that bone remodelling biomarkers might be involved in 
the progression of coronary artery calcification seemed to be tricky and beyond any 
reasonable expectation. However, in 1995 Boström et al. first time proposed the possible 
mechanisms for bone formation in artery walls involving retention of pluripotent cells or 
osteoblastic immigration coupled with embryonic-like osteogenic program (Boström et al. 
1995). The main reason for understanding the regulatory mechanisms of vascular 
calcification was firstly related to therapeutic approaches to prevent and possibly reverse 
vascular mineralization (Demer , 1997;  Parhami  et al. 1997). The data from clinical studies 
regularly report an association between bone remodeling biomarkers and the presence, 
severity and progression of a broad range of cardiovascular diseases. Whether they are 
biomarkers or rather play a causal role in mediating or protecting against vascular injury is 
not clear. The mechanisms underlying the postulated role of bone remodelling biomarkers 
in atherosclerosis probably involve inflammation and calcification processes. 
This section will focus on the prognostic significance of plasma bone remodelling 
biomarkers levels in stable and unstable CAD. 
2.1 Biology of bone remodelling of biomarkers 
Vascular biomineralization in an atherosclerotic plaque results from an  imbalance in 
osteoblast- and osteoclast-like cells and the induction of vascular or immune cells 
differentiation into osteogenic cells (Demer & Tintut, 2008). Osteobalsts, osteoclasts and 
inflammatory cells are firmly involved in bone remodelling (Fig. 2). 
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Fig. 2. Bone remodelling osteoblasts and osteoclasts differentiation. Figure was produced 
using Servier Medical Art. 
 
 
Fig. 3. The role of osteoprotegerin (OPG) in pre-osteoclast differentiation. OPG trap and 
neutralize a soluble receptor activator of nuclear factor kappa-B ligand (RANKL) which 
activates osteoclasts by its receptor (RANK). Figure was produced using Servier Medical Art. 
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Mesenchymal stem cells are precursors for pre-osteoblasts. Osteoblasts activity leads to 
bone formation and mineralization, their differentiation and activity is mostly regulated by  
RANKL (receptor activator of nuclear factor kappa-B ligand) inducers, such as:  vitamin D 
(1,25[OH]2D), glucocorticosteroids, parathormone (PTH), prostaglandins (PGE2), 
lipopolysaccharides (LPS), histamine and pro-inflammatory cytokines: interleukins (IL-1 
and IL-11), tumor necrosisi factor alfa (TNF-ǂ) and others (Eriksen, 2010). RANKL is a 
surface-bound molecule (also known as CD254). It is found on osteoblasts and serves to 
stimulate osteoclasts by RANK (receptor activator of nuclear factor kappa-B) activation and 
RANK/RANKL axis has a core regulatory role in osteoblasts and osteoclasts signalling (Fig. 
3) (Caidahl et al., 2010). 
2.2 Osteoprotegerin and osteopontin as risk factors of coronary artery disease 
Several studies suggest the involvement of bone remodeling biomarkers  in coronary artery 
disease and related atherosclerotic disorders (Van Campenhout & Golledge, 2009; Venuraju 
et al. 2010). Prime regulators of bone remodelling, such as osteoprotegerin (OPG) and 
osteopontin (OPN), are significantly and independently associated with inflammatory 
processes and arterial hypertension and may exert substantial influence on the severity of 
cardiovascular disease. (Stępień et al., 2011) 
OPG is a soluble glycoprotein widely expressed in most human tissues including the bone 
(osteoblasts) and the vasculature (endothelial and vascular smooth muscle cells, VSMC) 
(Collin-Osdoby, 2004; Schoppet et al., 2002) that is implicated in the regulation of bone and 
vascular calcification. OPG is a member of the tumor necrosis factor (TNF)-related family 
and a part of the OPG/RANKL/RANK triad. OPG acts as a soluble secreted decay receptor 
for a receptor activator of nuclear factor kappa-B ligand (RANKL) and neutralize this 
essential cytokine required for the osteoclasts differentiation (Hsu et al., 1999) (Fig. 3).  
RANKL expressed on osteoblastic, stromal and T cells binds to RANK (osteoclast 
differentiation factor) on the surface of osteoclasts, monocytic and dendritic cells and 
mediates a cell-to-cell signal responsible for osteoclastogenesis (Yasuda et al. 1998). 
Additional roles in immunological responses include the RANK-RANKL binding between 
dendritic and T cells which enhances the immunostimulatory capacity of dendritic cells and 
T cell proliferation (Green & Flavel 1999). 
It was observed that opg-knockout mice (OPG -/-) develop early onset osteoporosis and 
arterial calcification (Bucay et al., 1998) and the restoration of the gene prevented osteoporosis 
progression and arterial calcification (Min et al., 2000). Increased OPG level has been observed 
in men with advanced CAD and plasma OPG level has proved to be an independent predictor 
of myocardial ischemia in asymptomatic diabetic patients (Avignon, 2007; Schoppet et al., 
2003). Moreover, increased OPG has been related to the number and vulnerability  of plaques 
as well as in carotid artery (Kadoglou et al., 2008; Vik et al. 2010) or coronary vessels 
(Palazzuoli at al., 2008), which suggests its involvement in the coronary disease progression 
(Mikami et al., 2008; Pedersen et al., 2010). Elevated OPG in plasma is univariable predictors of 
coronary artery calcification (CAC) progression (Anand et al., 2007). The sensitivity of OPG for 
detecting of CAC score higher than 200 Agatston units was 80% in patients with predialysis 
diabetic nephropathy (Schoppet et al., 2003).  However, in the large Norwegian study by 
Pederesen et al. (Pedersen et al., 2010), adjustment for conventional risk factors attenuated the 
risk estimates for OPG levels. Only the subgroup of patients with stable angina pectoris (SA) 
with levels above the 90th percentile was at risk all-cause mortality: 1.94 (1.18, 3.18), p=0.01; 
CAD mortality: 2.29 (1.16, 4.49), p=0.02; and MI: 1.76 (1.02, 3.06), p=0.04.  
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In patients with acute coronary syndromes (ACS) the baseline OPG concentrations were 
strongly associated with increased long-term mortality (hazard ratio [HR] for log 
transformed OPG level 1.7 [range 1.5 to 1.9] p<0.0001) and heart failure hospitalizations (HR 
2.0 [range 1.6 to 2.5]; p < 0.0001) but weaker with recurrent MI (HR 1.3 [range 1.0 to 1.5]; p = 
0.02) and not with stroke (HR 1.2 [range 0.9 to 1.6]; p = 0.35). The association remained 
significant after adjustment for conventional risk markers (Omland et al., 2008). In 
apparently healthy individuals (the European Prospective Investigation into Cancer in 
Norfolk – EPIC Norfolk cohort) high serum concentrations of OPG and soluble RANKL 
were associated with an increased risk of future CAD (Semb et al., 2009). OPG showed a 
significant association with the risk of future coronary events in both sexes. This association 
remained statistically significant after adjustment for traditional cardiovascular risk factors 
(i.e. age, diabetes, systolic blood pressure, smoking, total cholesterol and HDL cholesterol). 
OPN is secreted as a calcium-binding glycophosphoprotein that has been implicated in bone 
remodeling and inflammation as well. Similarly to OPG, osteopontin is widely distributed 
in different human cells including osteoblasts, lymphocytes, macrophages, endothelial cells 
and vascular smooth muscle cells (Brown et al., 1992).  
OPN is a cytokine and has the ability to stimulate migration of macrophages and osteoclasts 
(Giachelli et al, 1998; Suzuki et al., 2002) and proliferation of osteoclasts and vascular 
smooth muscle cells (Giachelli et al, 1998; Liaw et al., 1994). A growing body of experimental 
evidence suggests that OPN overexpression plays an essential role in modulating 
compensatory cardiac fibrosis and hypertrophy (Xie et al., 2004; Singh et al. 2010). OPN acts 
through different integrins and thus has a great potential to regulate populations of different 
cells on the molecular and cellular levels (Bazzichi et al., 2009; Burke et al.,  2009). OPN 
plays a pivotal role in inflammation and atherosclerotic plaque formation in an animal 
model (Scatena et al., 2007). Recent data has indicated a high predictive value of OPN for 
secondary manifestations of atherosclerotic disease (e.g. cardiovascular death, myocardial 
infarction, stroke, and endovascular interventions) in a 3-year follow-up of patients 
undergoing carotid surgery (de Kleijn et al., 2010). 
Baseline levels of OPN are independent predictors of future adverse cardiac events in 
patients with chronic coronary syndrome (CCS), and may be useful for risk stratification 
(Minoretti et al., 2006). Recent data have indicated a high predictive value of OPN for 
secondary manifestations of atherosclerotic disease (e.g. cardiovascular death, MI, stroke 
and endovascular interventions) in a 3-year follow-up of patients undergoing carotid 
surgery. In a prospective study by Gogo et al. (Gogo et al., 2006), the association between 
angiographically quantified coronary artery calcification and OPG was not found. Detection 
of coronary calcification by coronary angiography may underestimate the calcification 
burden, thus synergistic diagnostics of coronary calcification should utilize more sensitive 
techniques of MSCT (Willemsen et al., 2009). However, in patients with CAD undergoing 
percutaneous coronary intervention (PCI) the highest OPN levels were associated with both 
plaque progression and restenosis in a stent (p=0.003). In addition, OPN, IL-6, and CRP 
were higher in patients with ACS than in those with CCS (analysis of variance: p<0.001, 
p<0.05 and p<0.05, respectively) (Mazzone et al, 2011). 
A question arises as to whether peripheral vascular function (calcification markers) matches 
the coronary arteries (calcification) and thus, whether it may serve as a surrogate marker to 
identify individuals with increased hazard of  CAD and mortality (de Kleijn et al., 2010; Lieb 
et al., 2010; Scatena et al., 2007). Therefore bone-matrix proteins combined with 
cardiovascular imaging  could be potential markers for vulnerable coronary artery  plaques. 
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3. Microparticles 
Microparticles (MP) are sub-micron sized cell membrane/cytoplasmic fragments that are 
released from the cell surface. There are two well-known cellular processes that can lead to 
the formation of MPs: chemical and physical cell activation (by agonists or shear stress, 
respectively), and apoptosis (Jimenez et al., 2003). However, the mechanisms that take place 
during MP formation are still not revealed. It seems that, the flopping of phosphatidylserine 
(PS) to the outer layer of the plasma membrane is pivotal. Finally, this process  leads to the 
formation and shedding of MPs from activated or apoptotic cells. In resting condition the 
membrane asymmetry is maintained by an aminophospholipid translocase with flippase 
activity. Bilayer asymmetry is disrupted in the consequence of the inhibition of flippase 
activity by calcium influx. Increased calcium ions concentrations activate calcium-
dependent calpains, which disturb cytoskeleton, promote the shedding of MPs (Morel et al., 
2011) and stimulate scramblase and floppase activities, which lead to the collapse of the 
membrane asymmetry (Freyssinet & Toti, 2010). 
MPs are qualitatively and quantitatively diverse and vary in diameter between 0.1 and 1.5 
µm and may harbor a number of cell surface proteins (Fig. 4). MPs are released from various 
cell types such as circulating blood cells (platelets, lymphocytes T and B, monocytes and 
erythrocytes) and cells of the vessel wall (endothelial and smooth muscle cells) (Amabile et 
al., 2010). 
 
 
Fig. 4. A platelet microparticle is carrying not only specific membrane adhesion proteins (P-
selectin, integrins – e. i. GPIIbIIIa, ), but also may harbour and transfer tissue factor (TF) 
which has its procoagulant potential and other functional effectors (E-selectin, von 
Willebrand factor, arachidonic acid, thromboxane A2), that can regulate aggregation, 
adhesion molecule expression, cell proliferation, apoptosis and endothelial migration. MPs 
may capsule messenger molecules (miRNA, DNA ?), cytokines, growth factors and calpains. 
Figure was produced using Servier Medical Art. 
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MPs from numerous cellular sources have been described in human plasma. They have 
received increasing attention as potential biomarkers of cell damage and activation or 
biovectors in blood coagulation, inflammation and cancer (Benameur et al., 2009;  Hoyer et 
al., 2010). In several pathological states like dilated cardiomyopathy, chronic renal failure or 
cerebrovascular disease, MPs were used as biomarkers to identify a disease or to detect 
complications linked to a given disease (Bulut et al. 2011; Faure et al., 2006; Jung et al., 2009). 
Numerous clinical studies have evaluated their usefulness in the stratification of patients at 
risk for vascular disorders and to monitor response to treatment. Circulating MPs may serve 
as a marker for cardiovascular events in CAD patients or as a predictor of acute allograft 
rejection after heart transplantation (Morel et al., 2008; Sinning et al., 2010). 
3.1 Microparticles discrimination and enumeration 
The high level of microparticles’ diversity may create a problem with compatible 
masurement of MPs using different analytical methods. The number of microparticles 
depend on the detection technique and a wide range of pre-analytical variables, i.e. blood 
collecting and handling, plasma preparation and storage conditions. Therefore, optimization 
and standardization of detection methods are important to define microparticles correctly 
and to avoid falsely high or low quantification. Even minor protocol changes significantly 
affected MP levels (Ayers et al., 2011). 
3.1.1 Flow cytometry in MP analysis 
Several research have evaluated the impact of these different parameters to propose a pre-
analytical protocol for MP analysis. Three ISTH Scientific and Standardization 
Subcommittees (SSC Vascular Biology, DIC, and Haemostasis &Malignancy) have initiated 
a project aimed at standardizing the enumeration of cellular MPs by means of flow 
cytometry method (FCM). The first collaborative workshop was set to establish the 
resolution and a threshold levels of the flow cytometers currently used in laboratories. 
Additionally, the interinstrument reproducibility of platelet MP enumeration in human 
plasma was analyzed (Lacroix et al., 2010).  The study included 40 laboratories and 59 flow 
instruments were validated according to the protocol based on Megamix beads calibration 
to discriminate microparticles between 0.5 μm and 0.9 μm using the forward scatter (FS) 
channeling (FSC) parameter (FS/FSC). After that, selected laboratories received PFP 
samples prepared as frozen aliquots by the core laboratory, to avoid any preanalytic-linked 
variability. The authors found high discrepancy among Becton Dickinson instruments, as 
well within low, medium and high values of MP: coefficients of variation were 78%, 60% 
and 91%, respectively. Whereas interlaboratory reproducibilities were 30% ,15% and 17% for 
low, medium and high values among Beckmann Coulter instruments. These data indicate 
that standardization of platelet MPs enumeration by FCM dependents on intrinsic 
characteristics of instruments. Moreover, standardization by calibrated beads such is useful 
tool for MP enumeration, however, calibrated beads do not reflect real condition of MPs in 
human plasma.  
3.1.2 Indirect methods for MP enumeration 
Alternative methods for MP enumeration based on TF-activity/antigen or platelet 
glycoprotein GPIb-integrin have been already described (Huise et al, 2009; Kuriyama et al., 
2010). The activity of tissue factor is evaluated using a chromogenic substrate for factor Xa, 
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thus the ability of MPs to promote factor X activation in the presence of factor VII using a 
chromogenic activity assay is utilized (Huise et al, 2009). Alternatively, TF antigen or 
activity can be measured in plasma or whole blood (Key NS & Mackman N, 2010). 
However, determination of microparticle size is not possible by such approaches. 
3.1.3 Pre-analytical variability in MP determination 
The analysis of different protocols used in MP preparation showed that washing, 
centrifugation, filtration of buffer and long-term freezing influenced significantly the MP 
quantification (Ayers et al., 2011; Dey-Hazra et al., 2010). Freezing samples at -80°C decreased 
MP levels (Ayers et al., 2011; Shah et al., 2009). The second collaborative workshop was 
dedicated to propose a common pre-analytical protocol useful for standardization of pre-
analytical variables in determination of MPs (Scientific and Standardization Committee 2010). 
3.1.4 Specific antigens in MP discrimination 
There are two main features of native MPs: the small size and the anionic phospholipid - PS 
on the outer leaflet of their membrane. In addition, MPs carry surface membrane antigens 
reflecting their cell of origin, including those induced by cellular activation, cell injury or 
apoptosis. These properties permit detection of specific subpopulations, such as endothelial, 
leucocyte or platelet-derived MPs (Diamant et al., 2004). 
PS is specifically bound to annexin V and is recommended as a distinguish marker for MP 
enumeration (Bulut et al., 2009; Shah et al. 2009). However, a number of evidence suggests 
that some vesicles derived from endothelial cells are PS-negative by annexin-V labelling 
(Jimenez et al., 2003; Sekuła et al., 2011). In platelet-poor plasma obtained from healthy 
donors, 80% of platelet-derived MPs failed to bind annexin V (Connor et al., 2010). In this 
case, a phalloidin-staining of actin filaments could be helpful in discrimination of MPs and 
other cell fragments (Mobarrez et al., 2010). Washing samples as well as double 
centrifugation result in decreased annexin-V (Ayers et al. 2011). 
3.1.4.1 Platelet MPs 
Platelets constitute the main source of circulating procoagulant MPs under many 
physiological and pathophysiological situations (Geiser, et al., 1998; Huise et al, 2009; 
Kuriyama et al., 2010). Procoagulant platelet derived MPs are enriched in P-selectin 
(CD62P), cell surface protein (CD63), integrins: GPIIbIIIa (ǂ2bǃ3), GPIIb (ǂ2b, CD41), GPIIIa 
(ǃ3, CD61) and GPIb (CD42b), tissue factor (CD142, TF) or calpains (Figure 4).  
Patients with unstable angina (UA) and AMI had a significantly increased number of 
procoagulant MPs: GPIIbIIIa-positive, CD62P-positive and CD41-positive (Huisse et al., 
2009; Morel et al., 2004; Stankiewicz et al., 2007; van der Zee et al. 2006). The total number of 
platelet-derived MPs were numerically higher in patients with no recanalisation compared 
to patients with recanalisation (Huisse et al., 2009). However, we observed paradoxically 
lower  number of CD62P-positive platelets in whole blood obtained from patients with ACS, 
than from SA patients, but the level of soluble P-selectin in plasma was significantly higher 
than in those with ACS (Figure 5). We may suspect that soluble P-selectin  levels are 
derivatives of platelet origin MPs (Chung et.al., 2009). 
3.1.4.2 Tissue factor-bearing MPs 
It was shown by cell sorting with the specific marker CD42b that under resting conditions, 
blood-borne TF was mainly harbored by platelet-derived MPs (Müller et al, 2003). In acute 
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coronary syndromes, TF triggers the formation of intracoronary thrombi following endothelial 
injury, activation of macrophages and apoptotosis of smooth muscle cells (SMCs) and 
macrophages (Morel et al, 2006). Apoptotic (annexin V-positive) MPs support a number of TF-
positive MPs from different origin. Apoptotic macrophages and SMCs are the main source of 
membrane-bound TF and they contribute to TF accumulation. Formation of TF triggering MPs 
rich in PS provides a suitable anionic phospholipid surface for assembly of the tenase and 
prothrombinase complexes and thrombin activation (Del Conde et al., 2005). 
 
 
Fig. 5. Platelet activation measured as a percentage of surface P-selectin-positive (CD62+) 
platelet (PLT), and by monocyte/platelet aggregates (MO/CD61+) and neutrophil/platelet 
aggregates (N/CD61+) in peripheral blood from patients with stable angina (SA) and acute 
myocardial infarction (AMI), and by levels of soluble P-selectin in patients with stable 
angina (SA), and acute myocardial infarction (AMI). Data are expressed as medians. 
*p<0.05,***p<0.00001 for the comparison. 
Additionally, an increased number of TF-positive (CD142-positive) MPs in patients with 
ACS was observed (Figure 6) (Huisse et al., 2009; Steppich et al., 2005). Moreover, elevated 
levels of different origin TF-bearing MPs were significantly higher within the occluded 
coronary artery than in peripheral blood samples (Morel et al. 2009). It suggests their 
contrubution in coronary atherothrombosis and in situ formation of procoagulat MPs. 
3.1.4.3 Endothelial microparticles 
Endothelial microparticles (EMPs) are an emerging marker of endothelial cell (EC) 
activation and dysfunction  and their circulating numbers are elevated in a number of 
pathologic states including cardiovascular disease. Many studies suggest that endothelial 
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cell-derived MPs have a paracrine role and contribute to the development of endothelial 
dysfunction in most cardiovascular diseases: CAD, ACS, MI, hypertension and congestive 
heart failure. Moreover, diabetes, end-stage renal failure and pulmonary or venous 
embolism are strong factors bringing about EMP shedding [Bal et al., 2010; Chirinos et. al., 
2005; Faure et al., 2006; Morel et al., 2004a]. In this case patients have marked activation of 
endothelial, platelet, and leukocyte MPs.  
Endothelial-derived microparticles (EMPs) may carry different endothelial originating 
coagulation factors, for example TF, which contribute to the clot formation and lysis (Chou 
et al., 2004; Stępień et al., 2007b). Patients with AMI displayed higher levels of all MPs than 
patients with SA and CD31-positive EMPs appeared the main source of procoagulant MPs 
(Morel et al., 2004b). In patients with ACS significant correlations between both the total 
 
 
Fig. 6. Representative dot plot of circulating microparticles (MPs) in a patient with acute 
coronary syndrome (ACS) and in a control voluntary. A, C - flow cytometry gating logic, 
MPs were initially gated by forward (FCS-H) and side scatter (SSC-H) in logarithmic scale; 
B, D - fluorescence plots show MPs binding of annexin V-FITC (FL1-H) and anti-CD142-PE 
(FL2-H) monoclonal antibody. 
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number as well as the level of CD34, CD51 and CD142 were observed (Stankiewicz et al., 
2007). Moreover, increased number of EMPs (E-cadherin/CD144-positive MPs) was an 
independent predictor of future cardiovascular events (HR 2.42 [range 1.03 to 5.68), p=0.04), 
but not for all-cause mortality (HR 2.10 [range 0.83 to 5.32] p=0.12) in patients with heart 
failure (Nozaki et al., 2010) and the assessment of EMPs improved prediction of future 
cardiovascular events in patients with CAD (Nozaki et al., 2009).  
4. Clotting 
Clotting is a rapid and highly dynamic process,  which involves both platelets and 
coagulation factors. To monitor the clotting process a lot of instrumentations and methods 
are engaged: i) clotting times: the activated partial thromboplastin time (aPTT) and the 
prothrombin time (PT); ii) thromboelastography; iii) assessment of thrombin generation 
markers and thrombin inhibitors; iv) the real-time monitoring of thrombin generation. This 
section will focus on the prognostic significance of thrombin generation markers in stable 
and unstable CAD. 
4.1 Markers of thrombin generation in CAD patients 
Antithrombin (AT) appears to be the most important stoichiometric inhibitor which forms 
equimolar complexes with thrombin molecules – TAT (thrombin-antithrombin) complexes. 
A concentration of TAT complexes measured in peripheral venous blood and in blood 
collected at the site of microvascular injury reflect thrombin generation. TAT complexes are 
expressed during clot formation and there are (alike fibrinopeptide A and F 1+2 fragments) 
markers of thrombin activation (Pelzer et al., 1988; Pelzer et al., 1991). These markers are 
elevated in pro-thrombotic conditions In patients with cardiovascular disease, the detection 
of a prothrombotic state may have two major implications: i) to extend the duration and ii) 
to monitor the dose of anticoagulation after cardiac intervention. The thrombin plasma 
activity is very firmly associated with CAD. 
The potential coagulation activity in plasma can be evaluated by the rate of thrombin 
formation and the total amount of formed thrombin is measured by means of chromogenic 
or fluorescence methods (Devreese et al., 2007; Hemker et al., 2002). This thrombin potential 
in plasma can be assessed by different methods and the Calibrated Automated 
Thrombogram (CAT) applies a fluorogenic substrate. A chromogenic substrate is used in 
Behring Coagulation System (BCS). In both methods thrombin generation is activated by 
diluted recombinant tissue factor (TF), but in the BCS method a non-defined fibrin 
aggregation inhibitor is present. Both methods are applied in diagnostics. In CAT a 
calibration factor is measured in a plasma sample identical to that in which thrombin 
generation is being determined and the course of the calibration factor is assessed during 
the entire measurement (Figure 7). Thrombin generation assays seem to be useful in  
endogenous TF assessment (Ollivier et al. 2010; Stępień et al., 2007a).  
4.2 Blood sampling for coagulation markers assessment 
The most important think in coagulation diagnostics is to apply a reliably sampling method. 
To ensure accurate measurement samples must be collected in the circumstances under 
which false elevations of molecular markers of hemostatic and fibrinolytic activation will 
not occur. Thus, atraumatic antecubital venipuncture into vacutainer containing buffered 
sodium citrate is essential and the contamination with calcium or magnesium should be 
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avoided (van den Besselaar et al., 2007; Stegmar et al., 2007). To avoid activation of 
coagulation by tissue thromboplastin, each collection of citrated plasma should be preceded 
by a serum tube. Duration of needle puncture, rather than duration of tourniquet use, 
produced the greatest elevation in plasma levels of TAT and F1+2 (Omote et al., 2008). 
 
 
Fig. 7. The rate of thrombin formation is presented as the thrombin concentration against  
time curve. Three parameters are presented: lag time (Tlag),  peak height (Cmax) and 
endogenous thrombin potential (ETP). 
4.3 Prognostic value of thrombin generation in cardiac events 
Increased circulating levels of thrombin and its markers characterize ACS (Ardissino et al., 
2003; Takano et al., 1991). Plasma F1+2, normally about 1 nM, is roughly 1.5-2-fold higher 
than observed in SA patients, reaching maximum values in AMI (Ardissino et al., 2001). U-
shaped relationship between plasma prothrombin fragment 1+2 levels and the risk of 
developing cardiac death or renewed myocardial infarction was observed. Intermediate 
levels (1.5-1.9 nM) were associated with the lowest risk, whereas both higher (>1.9 nM) and 
lower (< 1.5 nM) values were associated with an increased risk (RR 1.56 [range 1.25 to 2.28] 
and RR 1.35 [range 1.11 to 1.86], respectively) (Ardissino et al., 2003). Hypercoagulable state 
measured as thrombin-antithrombin complexes (TAT) levels and as calibrated automated 
thrombogram reflects vascular impairment in CAD patients (Stępień et al., 2007a). It was 
observed that high TAT levels may predict mortality in chronic heart disease group after 
adjustment for classic risk factors (Marcucci et al., 2006). In empirical reconstruction, 
simulated maximum thrombin levels (p<0.01) and rates (p<0.01) were 50% higher with ACS 
while the initiation phases of thrombin generation were shorter than in patients with stable 
CAD (Brummel-Ziedins et al., 2008). Elevated levels of thrombin derivatives are associated 
with clinical risk factors for stroke (Lane et al., 1983; Takano et al., 1991). Elevated thrombin 
concentration reflects hypercoagulable state in patients with hypertension (Hoeper et al, 
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1998; Kłoczko et al., 1996), hyperglycaemia (Undas et al., 2008) and hypercholesterolemia 
(Wada et al., 1992; Sanguigni  et al., 2005; Undas et al., 2005).  
5. Conclusion 
Endothelial and platelets activation leading to cardiovascular complications can be 
evaluated quantitatively by measurement of plasma levels of circulating MPs. Moreover, a 
multiple biomarkers strategy that includes bone remodeling  biomarkers (OPG, OPN) and 
clotting properties can provide better risk stratification of cardiovascular events.  
Development and discovery of new biomarkers may improve clinical assessment of patients  
who might benefit more from treatment. Synergistic strategies in diagnostics seem to be 
more advantageous than routine method in prognosis and patients’ management. 
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